Stockreport

Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus

Galapagos NV - American Depositary Shares  (GLPG) 
Last galapagos nv - american depositary shares earnings: 10/24 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: glpg.com/company-overview
PDF GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of d [Read more]